Skip to main content

Induction of Labor Affected Fetus / Newborn

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Medicem
MedicemCzech Republic - Kamenné Žehrovice
1 program
1
Dilapan-SPhase 31 trial
Active Trials
NCT03001661Completed674Est. Feb 2021
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
Outpatient Dinoprostone 10mgPHASE_31 trial
Active Trials
NCT03806231Terminated8Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsOutpatient Dinoprostone 10mg
MedicemDilapan-S

Clinical Trials (2)

Total enrollment: 682 patients across 2 trials

NCT03806231Ferring PharmaceuticalsOutpatient Dinoprostone 10mg

A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening

Start: Aug 2019Est. completion: Apr 20208 patients
Phase 3Terminated

An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt

Start: Dec 2017Est. completion: Feb 2021674 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.